These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 17024115)

  • 1. Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells.
    Kraus M; Rückrich T; Reich M; Gogel J; Beck A; Kammer W; Berkers CR; Burg D; Overkleeft H; Ovaa H; Driessen C
    Leukemia; 2007 Jan; 21(1):84-92. PubMed ID: 17024115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells.
    Rückrich T; Kraus M; Gogel J; Beck A; Ovaa H; Verdoes M; Overkleeft HS; Kalbacher H; Driessen C
    Leukemia; 2009 Jun; 23(6):1098-105. PubMed ID: 19225532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
    Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
    J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. G(alpha)12/13 inhibition enhances the anticancer effect of bortezomib through PSMB5 downregulation.
    Yang YM; Lee S; Nam CW; Ha JH; Jayaraman M; Dhanasekaran DN; Lee CH; Kwak MK; Kim SG
    Carcinogenesis; 2010 Jul; 31(7):1230-7. PubMed ID: 20478922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
    Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
    Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells.
    Altun M; Galardy PJ; Shringarpure R; Hideshima T; LeBlanc R; Anderson KC; Ploegh HL; Kessler BM
    Cancer Res; 2005 Sep; 65(17):7896-901. PubMed ID: 16140960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point mutation of the proteasome beta5 subunit gene is an important mechanism of bortezomib resistance in bortezomib-selected variants of Jurkat T cell lymphoblastic lymphoma/leukemia line.
    Lü S; Yang J; Song X; Gong S; Zhou H; Guo L; Song N; Bao X; Chen P; Wang J
    J Pharmacol Exp Ther; 2008 Aug; 326(2):423-31. PubMed ID: 18502982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells.
    Fuchs D; Berges C; Opelz G; Daniel V; Naujokat C
    J Cell Biochem; 2008 Jan; 103(1):270-83. PubMed ID: 17516511
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib.
    Berkers CR; Verdoes M; Lichtman E; Fiebiger E; Kessler BM; Anderson KC; Ploegh HL; Ovaa H; Galardy PJ
    Nat Methods; 2005 May; 2(5):357-62. PubMed ID: 15846363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression of catalytic proteasome subunits and resistance toward proteasome inhibition of B lymphocytes from patients with primary sjogren syndrome.
    Martinez-Gamboa L; Lesemann K; Kuckelkorn U; Scheffler S; Ghannam K; Hahne M; Gaber-Elsner T; Egerer K; Naumann L; Buttgereit F; Dörner T; Kloetzel PM; Burmester GR; Faustman DL; Feist E
    J Rheumatol; 2013 May; 40(5):663-73. PubMed ID: 23504381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.
    Franke NE; Niewerth D; Assaraf YG; van Meerloo J; Vojtekova K; van Zantwijk CH; Zweegman S; Chan ET; Kirk CJ; Geerke DP; Schimmer AD; Kaspers GJ; Jansen G; Cloos J
    Leukemia; 2012 Apr; 26(4):757-68. PubMed ID: 21941364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors.
    Niewerth D; Franke NE; Jansen G; Assaraf YG; van Meerloo J; Kirk CJ; Degenhardt J; Anderl J; Schimmer AD; Zweegman S; de Haas V; Horton TM; Kaspers GJ; Cloos J
    Haematologica; 2013 Dec; 98(12):1896-904. PubMed ID: 24056819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer.
    de Wilt LH; Jansen G; Assaraf YG; van Meerloo J; Cloos J; Schimmer AD; Chan ET; Kirk CJ; Peters GJ; Kruyt FA
    Biochem Pharmacol; 2012 Jan; 83(2):207-17. PubMed ID: 22027222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits.
    Busse A; Kraus M; Na IK; Rietz A; Scheibenbogen C; Driessen C; Blau IW; Thiel E; Keilholz U
    Cancer; 2008 Feb; 112(3):659-70. PubMed ID: 18181098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
    Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
    J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells.
    Fujita T; Doihara H; Washio K; Ino H; Murakami M; Naito M; Shimizu N
    Anticancer Drugs; 2007 Jul; 18(6):677-86. PubMed ID: 17762396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies.
    Caravita T; de Fabritiis P; Palumbo A; Amadori S; Boccadoro M
    Nat Clin Pract Oncol; 2006 Jul; 3(7):374-87. PubMed ID: 16826218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome inhibition: a new approach for the treatment of malignancies.
    Spano JP; Bay JO; Blay JY; Rixe O
    Bull Cancer; 2005 Nov; 92(11):E61-6, 945-52. PubMed ID: 16316823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro.
    Horton TM; Gannavarapu A; Blaney SM; D'Argenio DZ; Plon SE; Berg SL
    Cancer Chemother Pharmacol; 2006 Jul; 58(1):13-23. PubMed ID: 16292537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.